Physician profile
Ryan M Bednar
NPI 1376015594
$4,894.89
in general payments reported to CMS, 2019-2025
19 companies · $1,105 in 2025
The $1,105 reported for 2025 was more than what 82% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $664 · 2022: $1,552 · 2023: $716 · 2024: $857 · 2025: $1,105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,629 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,629.20 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,004.12 | 2021-2025 | |
| Lundbeck LLC | $872.70 | 2021-2025 | Abilify Maintena, Rexulti |
| Otsuka America Pharmaceutical, INC. | $648.29 | 2021-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $512.11 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $462.70 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Alkermes, INC. | $204.30 | 2021-2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $199.72 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $192.46 | 2024-2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $192.28 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $174.85 | 2022-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $155.41 | 2022-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $65.23 | 2022 | |
| Noven Therapeutics, LLC | $52.50 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $48.89 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $43.42 | 2023-2024 | Qelbree, Qelbree |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Luye Pharma (USA) LTD. | $17.87 | 2025 | Erzofri Extended-Release |
| Idorsia Pharmaceuticals US INC | $17.37 | 2022 | |
| Sage Therapeutics, LLC | $15.49 | 2025 | Zurzuvae |
| Indivior INC. | $15.18 | 2023 | Perseris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Bednar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.